Reference tissue-based kinetic evaluation of 18F-AV-1451 for tau imaging

Journal of Nuclear Medicine

Volumn 58, Issue 2, 2017, Pages 332-338

  Baker, Suzanne L ^a   Lockhart, Samuel N ^b   Price, Julie C ^c   He, Mark ^b   Huesman, Ronald H ^a   Schonhaut, Daniel ^d   Faria, Jamie ^a   Rabinovici, Gil ^d   Jagust, William J ^a,b  

^a LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

18F AV 1451; Alzheimer's; Kinetics; Tau

Indexed keywords

FLORTAUCIPIR F 18; TAU PROTEIN; 7-(6-FLUOROPYRIDIN-3-YL)-5H-PYRIDO(4,3-B)INDOLE; BIOLOGICAL MARKER; CARBOLINE DERIVATIVE; RADIOPHARMACEUTICAL AGENT;

ADULT; ALZHEIMER DISEASE; ARTICLE; BRAIN REGION; CALCULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BINDING; DRUG SCREENING; FEMALE; GRAY MATTER; HUMAN; IMAGE SEGMENTATION; IMAGING SOFTWARE; IN VIVO STUDY; MALE; MATHEMATICAL MODEL; MIDDLE AGED; NEUROIMAGING; NONDISPLACEABLE BINDING POTENTIAL; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PET-CT SCANNER; PHARMACOKINETIC PARAMETERS; POSITRON EMISSION TOMOGRAPHY; QUANTITATIVE ANALYSIS; SIMPLIFIED REFERENCE TISSUE MODEL; SIMPLIFIED REFERENCE TISSUE MODEL 2; STANDARD; SUV RATIO; TAUOPATHY; VOLUME OF DISTRIBUTION RATIO; AGED; BIOLOGICAL MODEL; BRAIN; COMPUTER SIMULATION; DIAGNOSTIC IMAGING; IMAGE ENHANCEMENT; KINETICS; METABOLIC CLEARANCE RATE; METABOLISM; MOLECULAR IMAGING; PROCEDURES; PROTEIN ANALYSIS; REFERENCE VALUE; STANDARDS; UNITED STATES;

AGED; ALZHEIMER DISEASE; BIOMARKERS; BRAIN; CARBOLINES; COMPUTER SIMULATION; FEMALE; HUMANS; IMAGE ENHANCEMENT; KINETICS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MODELS, BIOLOGICAL; MOLECULAR IMAGING; POSITRON-EMISSION TOMOGRAPHY; PROTEIN INTERACTION MAPPING; RADIOPHARMACEUTICALS; REFERENCE VALUES; TAU PROTEINS; UNITED STATES;

EID: 85011945209     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.116.175273     Document Type: Article

References (25)

1. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl). 1991;82:239-259.
2. Crary JF, Trojanowski JQ, Schneider JA, et al. Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol (Berl). 2014;128:755-766.
3. Villemagne VL, Fodero-Tavoletti MT, Masters CL, Rowe CC. Tau imaging: early progress and future directions. Lancet Neurol. 2015;14:114-124.
4. 18F]THK-523 and other amyloid imaging tracers to Alzheimer's disease pathology. Eur J Nucl Med Mol Imaging. 2013;40:125-132.
5. Fodero-Tavoletti MT, Furumoto S, Taylor L, et al. Assessing THK523 selectivity for tau deposits in Alzheimer's disease and non-Alzheimer's disease tauopathies. Alzheimers Res Ther. 2014;6:11.
6. Villemagne VL, Furumoto S, Fodero-Tavoletti MT, et al. In vivo evaluation of a novel tau imaging tracer for Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2014;41:816-826.
7. 18F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease. J Nucl Med. 2013;54:1420-1427.
8. 18F-THK5105 PET. Brain. 2014;137:1762-1771.
9. Okamura N, Harada R, Furumoto S, et al. Tau PET imaging in Alzheimer's disease. Curr Neurol Neurosci Rep. 2014;14:500.
10. 18F-THK5351: a novel PET radiotracer for imaging neurofibrillary pathology in Alzheimer disease. J Nucl Med. 2016;57:208-214.
11. 18F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease. Alzheimers Dement. 2013;9:666-676.
12. Chien DT, Szardenings AK, Bahri S, et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808. J Alzheimers Dis. 2014;38:171-184.
13. Lammertsma AA, Hume SP. Simplified reference tissue model for PET receptor studies. Neuroimage. 1996;4:153-158.
14. Logan J, Fowler JS, Volkow ND, et al. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab. 1996;16:834-840.
15. Gunn RN, Lammertsma AA, Hume SP, Cunningham VJ. Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. Neuroimage. 1997;6:279-287.
16. Wu Y, Carson RE. Noise reduction in the simplified reference tissue model for neuroreceptor functional imaging. J Cereb Blood Flow Metab. 2002;22:1440-1452.
17. Murtagh F. A survey of recent advances in hierarchicial clustering algorithms. Comput J. 1984;26:354-359.
18. Akaike H. A new look at the statistical model identification. IEEE Trans Automat Contr. 1974;19:716-723.
19. Landaw EM, DiStefano JJ, III. Multiexponential, multicompartmental, and noncompartmental modeling. II. Data analysis and statistical considerations. Am J Physiol. 1984;246:R665-R677.
20. Bennett DA, Schneider JA, Arvanitakis Z, et al. Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology. 2006;66:1837-1844.
21. 18FAV-1451 (T807) in subjects with normal cognitive function, mild cognitive impairment, and Alzheimer's disease. J Nucl Med. May 5, 2016 [Epub ahead of print].
22. Johnson KA, Schultz A, Betensky RA. Tau PET imaging in aging and early Alzheimer's disease. Ann Neurol. 2016;79:110-119.
23. 18F]AV-1451 uptake and gadolinium concentration in young and older subjects. Poster presented at: the Human Amyloid Imaging Meeting; Miami, FL; January 14, 2016.
24. Marquié M, Normandin MD, Venderburg CR, et al. Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann Neurol. 2015;78:787-800.
25. Salinas CA, Searle GE, Gunn RN. The simplified reference tissue model: model assumption violations and their impact on binding potential. J Cereb Blood Flow Metab. 2015;35:304-311.